North America Anti Obesity Drugs Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

North America Anti Obesity Drugs Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Country Analysis

North America Anti Obesity Drugs Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
North America Anti Obesity Drugs Totalxxxxxxxxxxxx30.07%
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Type breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.

Prescription Drugs North America Anti Obesity Drugs Market Analysis
XX
Prescription Drugs Market Size 2025
XX %
CAGR
Locked · Full data in paid report
OTC Drugs North America Anti Obesity Drugs Market Analysis
XX
OTC Drugs Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Anti Obesity Drug Market

Novo Nordisk A/S

Novo Nordisk A/S is a pharmaceutical company involved in the manufacturing of medicines or drugs for diabetes and obesity care, and rare diseases. The company has a presence in over 170 countries. The company has 10 research and development centers in five countries (China, Denmark, India, the UK, and the US), and 16 production sites in nine countries (Algeria, Brazil, China, Denmark, France, Iran, Japan, Russia, and US).

Anti Obesity Drug Industry News

February 2024

Novo Nordisk to acquire three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction 

Novo Nordisk announced that the company has agreed to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in Somerset, New Jersey (US). Novo Nordisk and Catalent have a long-standing collaboration.

(Source-https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167017)

August 2023

Novo Nordisk strikes $11bn deal to expand production of weight loss drug Novo Nordisk has agreed to acquire three manufacturing sites for $11bn, as the Danish drugmaker races to expand production of the weight loss drugs whose runaway success has sent the company’s valuation beyond $500bn.

The group reported record sales for 2023, driven by surging demand for its diabetes and anti-obesity drugs Ozempic and Wegovy. However, Novo Nordisk warned that supply chain bottlenecks were hampering its ability to produce enough of the best-selling treatments.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Company 1••• ••• ••• •••
Company 2••• ••• ••• •••
Company 3••• ••• ••• •••
Company 4••• ••• ••• •••
Company 5••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

North America Anti Obesity Drugs market Analysis

North America Anti Obesity Drugs market size was $2,799.66 Million in 2024 and it is forecasted to reach $13,150.65 Million by 2030. Anti Obesity Drugs Industry's Compound Annual Growth Rate was 30.07% from 2024 to 2031.

North America accounted for the share of 42.34% in 2023, with CAGR of 30.07% for the forecasted period. In the United States, 1 in 5 children and adolescents and 2 out of 5 adults are obese, while many more are overweight. Type 2 diabetes, heart disease, stroke, and some cancers are just a few of the major health issues that obesity is associated with. The prevalence of obesity in several racial/ethnic groups raises their likelihood of developing chronic illnesses. In addition, The Centers for Disease Control and Prevention estimate that over 40% of Americans are obese, and that percentage has risen by almost 40% in the last 20 years. Individuals who are obese have a higher risk of developing dementia, arthritis, many types of cancer, and cardiovascular disease. Moreover, according to the American Academy of Pediatrics' standards, 14.4 million children and adolescents in the United States suffer from obesity and overweight, which is considered "one of the most common pediatric chronic diseases."
For instance, the therapeutic landscape has changed as a result of a new generation of anti-obesity medications that offer effective new therapies for weight loss but also raise questions about how best to use them and where to put lifestyle-based interventions, which have long had a central position, in relation to them. The medications, known as GLP-1 receptor agonists, were created to treat Type 2 diabetes, whose incidence has increased dramatically in recent years along with obesity trends in the United States. In addition to controlling blood sugar, these drugs cause weight loss, an effect that has drawn attention from the general public and pharmaceutical companies, who have responded by developing customized formulations to aid in weight loss.

The medical devices and consumables industry is growing rapidly, driven by aging populations, rising healthcare spending, and supportive regulations, boosting demand for implants, assistive tech, and home monitoring. Challenges include strict regulations, high R&D costs, and supply chain risks, but opportunities lie in emerging markets, health-tech partnerships, and eco-friendly devices. Key trends such as AI, precision medicine, and sustainable innovations are transforming healthcare and accelerating market growth.

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The North America Anti Obesity Drugs Market Analysis is witnessing significant growth in the near future.

In 2023, the Prescription Drugs segment accounted for a notable share of the North America Anti Obesity Drugs Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst at Cognitive Market Research
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

North America Anti Obesity Drugs Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers and others are profiled in the report.
Segments include Type, Distributional Channel and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

North America Anti Obesity Drugs Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
By ProductPrescription Drugs, OTC Drugs
By Distributional ChannelHospital Pharmacy, Retail, Online Pharmacy
ByAction PathwayPeripherally acting drug, Centrally acting drug
By route of A dministrationOral Route, Subcutaneous Route
List of CompetitorsNovo Nordisk A/S, GlaxoSmithKline plc, Novartis AG, VIVUS LLC, Currax Pharmaceuticals, Kintai Therapeutics, Boehringer Ingelheim International GmbH, Rhythm Pharmaceuticals, Inc., Gelesis, Zydus Lifesciences Ltd.

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Top Players Ranking 2024
      • 1.1.2 New Product Launch Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Novo Nordisk A/S
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 R&D Investment (Subject to data availability)
        • 1.2.1.4 Financials (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 GlaxoSmithKline plc
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 R&D Investment (Subject to data availability)
        • 1.2.2.4 Financials (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Novartis AG
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 R&D Investment (Subject to data availability)
        • 1.2.3.4 Financials (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 VIVUS LLC
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 R&D Investment (Subject to data availability)
        • 1.2.4.4 Financials (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Currax Pharmaceuticals
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 R&D Investment (Subject to data availability)
        • 1.2.5.4 Financials (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Kintai Therapeutics
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 R&D Investment (Subject to data availability)
        • 1.2.6.4 Financials (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Boehringer Ingelheim International GmbH
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 R&D Investment (Subject to data availability)
        • 1.2.7.4 Financials (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Rhythm Pharmaceuticals
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 R&D Investment (Subject to data availability)
        • 1.2.8.4 Financials (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Inc.
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 R&D Investment (Subject to data availability)
        • 1.2.9.4 Financials (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Gelesis
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 R&D Investment (Subject to data availability)
        • 1.2.10.4 Financials (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Zydus Lifesciences Ltd.
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 R&D Investment (Subject to data availability)
        • 1.2.11.4 Financials (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis

  • Chapter 2. Global Anti Obesity Drugs Market Analysis

    • 2.1 Global Anti Obesity Drugs Market Analysis
    • 2.2 Global Anti Obesity Drugs Market Analysis by By Product
    • 2.3 Global Anti Obesity Drugs Market Analysis by By Distributional Channel
    • 2.4 Global Anti Obesity Drugs Market Analysis by ByAction Pathway
    • 2.5 Global Anti Obesity Drugs Market Analysis by By route of A dministration

  • Chapter 3. North America Anti Obesity Drugs Market Analysis

    • 3.1 North America Anti Obesity Drugs Market Analysis
    • 3.2 North America Anti Obesity Drugs Market Analysis by Country
    • 3.3 North America Anti Obesity Drugs Market Analysis by By Product
    • 3.4 North America Anti Obesity Drugs Market Analysis by By Distributional Channel
    • 3.5 North America Anti Obesity Drugs Market Analysis by ByAction Pathway
    • 3.6 North America Anti Obesity Drugs Market Analysis by By route of A dministration
    • 3.7 North America Anti Obesity Drugs Market Analysis by Key Players

  • Chapter 4. United States Anti Obesity Drugs Market Analysis

    • 4.1 United States Anti Obesity Drugs Market Analysis
    • 4.2 United States Anti Obesity Drugs Market Analysis by By Product
    • 4.3 United States Anti Obesity Drugs Market Analysis by By Distributional Channel
    • 4.4 United States Anti Obesity Drugs Market Analysis by ByAction Pathway
    • 4.5 United States Anti Obesity Drugs Market Analysis by By route of A dministration
    • 4.6 United States Anti Obesity Drugs Market Analysis by Key Players

  • Chapter 5. Canada Anti Obesity Drugs Market Analysis

    • 5.1 Canada Anti Obesity Drugs Market Analysis
    • 5.2 Canada Anti Obesity Drugs Market Analysis by By Product
    • 5.3 Canada Anti Obesity Drugs Market Analysis by By Distributional Channel
    • 5.4 Canada Anti Obesity Drugs Market Analysis by ByAction Pathway
    • 5.5 Canada Anti Obesity Drugs Market Analysis by By route of A dministration
    • 5.6 Canada Anti Obesity Drugs Market Analysis by Key Players

  • Chapter 6. Mexico Anti Obesity Drugs Market Analysis

    • 6.1 Mexico Anti Obesity Drugs Market Analysis
    • 6.2 Mexico Anti Obesity Drugs Market Analysis by By Product
    • 6.3 Mexico Anti Obesity Drugs Market Analysis by By Distributional Channel
    • 6.4 Mexico Anti Obesity Drugs Market Analysis by ByAction Pathway
    • 6.5 Mexico Anti Obesity Drugs Market Analysis by By route of A dministration
    • 6.6 Mexico Anti Obesity Drugs Market Analysis by Key Players

  • Chapter 7. By Product Analysis

    • 7.1 Prescription Drugs
    • 7.2 OTC Drugs

  • Chapter 8. By Distributional Channel Analysis

    • 8.1 Hospital Pharmacy
    • 8.2 Retail
    • 8.3 Online Pharmacy

  • Chapter 9. ByAction Pathway Analysis

    • 9.1 Peripherally acting drug
    • 9.2 Centrally acting drug

  • Chapter 10. By route of A dministration Analysis

    • 10.1 Oral Route
    • 10.2 Subcutaneous Route

  • Chapter 11. Qualitative Analysis (Subject to Data Availability)

    • 11.1 Market Drivers
    • 11.2 Market Restraints
    • 11.3 Market Trends
    • 11.4 Market Opportunity
    • 11.5 Technological Road Map (Subject to Data Availability)
    • 11.6 Product Life Cycle (Subject to Data Availability)
    • 11.7 Customer and Buyer Behavior Analysis
      • 11.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 11.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 11.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 11.7.4 Pricing, Affordability & Value Perception Analysis
      • 11.7.5 Customer Segmentation & Demand Pattern Analysis
    • 11.8 Industrial Chain Analysis (Subject to Data Availability)
      • 11.8.1 Industry Chain Analysis
      • 11.8.2 Manufacturing Cost Analysis
      • 11.8.3 Supply Side Analysis
        • 11.8.3.1 Raw Material Analysis
        • 11.8.3.2 Raw Material Procurement Analysis
        • 11.8.3.3 Raw Material Price Trend Analysis
    • 11.9 PESTEL Analysis
      • 11.9.1 Environmental Factors
      • 11.9.2 Legal Factors
      • 11.9.3 Technological Factors
      • 11.9.4 Economic Factors
      • 11.9.5 Political Factors
      • 11.9.6 Social Factors
    • 11.10 Porter’s Five Forces Analysis
      • 11.10.1 Degree of Competition
      • 11.10.2 Threat of Substitutes
      • 11.10.3 Threat of New Entrants
      • 11.10.4 Bargaining Power of Buyers
      • 11.10.5 Bargaining Power of Suppliers
    • 11.11 Patent Analysis (Subject to Data Availability)
    • 11.12 ESG Analysis
    • 11.13 Geopolitical Outlook
      • 11.13.1 Global Power Realignment & Strategic Alliances
      • 11.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 11.13.3 International Trade Relations & Market Access Environment
      • 11.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 11.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 11.13.6 Technology Sovereignty & Digital Geopolitics
      • 11.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 11.14 AI & Market Transformation
      • 11.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 11.14.2 AI-Driven Transformation of Industry Value Chain
      • 11.14.3 Evolution of Business Models & Revenue Streams
      • 11.14.4 AI-Driven Product, Service & Innovation Transformation
      • 11.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 12. Research Findings

    • 12.1 Key Takeaways
    • 12.2 Analyst Point of View
    • 12.3 Assumptions and Acronyms

  • Chapter 13. Research Methodology and Sources

    • 13.1 Primary Data Collection
      • 13.1.1 Steps for Primary Data Collection
        • 13.1.1.1 Identification of KOL
      • 13.1.2 Backward Integration
      • 13.1.3 Forward Integration
      • 13.1.4 How Primary Research Help Us
      • 13.1.5 Modes of Primary Research
    • 13.2 Secondary Research
      • 13.2.1 How Secondary Research Help Us
      • 13.2.2 Sources of Secondary Research
    • 13.3 Data Validation
      • 13.3.1 Data Triangulation
    • 13.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the North America Anti Obesity Drugs Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 22+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Medical Devices and Consumables Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Anti Obesity Drugs Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america anti obesity drugs market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.